Epoetin delta
Dynepo (epoetin delta) is a protein pharmaceutical. Epoetin delta was first approved as Dynepo on 2002-03-18. It has been approved in Europe to treat anemia and chronic kidney failure.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
516 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 6 | 68 | 110 | 52 | 20 | 253 |
| Chronic renal insufficiency | D051436 | N18 | 4 | 7 | 19 | 6 | 8 | 44 | |
| Neoplasms | D009369 | C80 | — | 13 | 13 | 5 | 7 | 38 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 3 | 7 | 14 | 5 | 5 | 34 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 14 | 7 | 2 | — | 23 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 4 | 8 | 15 |
| Lymphoma | D008223 | C85.9 | 1 | 2 | 7 | 1 | 1 | 12 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 6 | 1 | — | 8 |
| Drug therapy | D004358 | — | 2 | 1 | 3 | — | 6 | ||
| Fatigue | D005221 | HP_0012378 | R53.83 | — | 2 | 1 | 1 | 2 | 6 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | — | 3 | 7 | — | 1 | 11 | |
| Plasma cell neoplasms | D054219 | — | 2 | 5 | — | 1 | 8 | ||
| Cerebral palsy | D002547 | G80 | 1 | 2 | 1 | — | 3 | 7 | |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 4 | 3 | 3 | — | — | 7 |
| Blood transfusion | D001803 | — | 4 | 5 | — | 1 | 7 | ||
| Orthopedic procedures | D019637 | — | 4 | 6 | — | — | 7 | ||
| Traumatic brain injuries | D000070642 | S06 | — | 3 | 4 | — | 1 | 6 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 3 | — | 1 | 5 |
| Precancerous conditions | D011230 | — | 2 | 2 | — | — | 4 | ||
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 2 | 2 | — | — | 4 |
Show 55 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | 3 | — | — | 2 | 14 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 5 | — | — | — | 5 |
| Reperfusion injury | D015427 | 1 | 1 | — | — | 1 | 3 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 1 | 3 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 1 | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 1 | — | — | — | 2 |
| Moyamoya disease | D009072 | EFO_0004250 | I67.5 | 1 | 1 | — | — | 1 | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | — | — | — | 2 |
| Replacement arthroplasty knee | D019645 | — | 1 | — | — | 1 | 2 | ||
| Chronic disease | D002908 | — | 1 | — | — | 1 | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Autoimmune hepatitis | D019693 | K75.4 | 1 | — | — | — | — | 1 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Alveolar bone loss | D016301 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Iron metabolism disorders | D019189 | E83.1 | — | — | — | — | 1 | 1 | |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
| Uterine diseases | D014591 | N85.9 | — | — | — | — | 1 | 1 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Myocardial reperfusion injury | D015428 | EFO_0002687 | — | — | — | — | 1 | 1 | |
| Hemiarthroplasty | D062785 | — | — | — | — | 1 | 1 | ||
| Fibrosis | D005355 | — | — | — | — | 1 | 1 | ||
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPOETIN DELTA |
| INN | epoetin delta |
| Description | Dynepo (epoetin delta) is a protein pharmaceutical. Epoetin delta was first approved as Dynepo on 2002-03-18. It has been approved in Europe to treat anemia and chronic kidney failure. |
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109093 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 474EI5756Y (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 88 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more